Methods Compared Classifying Intensity of Soil-Transmitted Helminth Infections
|
By LabMedica International staff writers Posted on 23 Jul 2020 |

Image: The FECPAKG2 is an internet connected, image based diagnostic platform scientifically validated to conduct fecal egg count (FEC) tests (Photo courtesy of Techion).
Soil-transmitted helminths (Ascaris lumbricoides, Trichuris trichiura) and the hookworms, Necator americanus and Ancylostoma duodenale affect one quarter of the world population, and are responsible for the loss of more than three million disability-adjusted life years (DALYs).
There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.
An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.
The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.
The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital
There are a variety of novel microscopy and DNA-based methods to identify soil-transmitted helminths, but it remains unclear whether applying current World Health Organization (WHO) thresholds on to these methods allows for a reliable classification of moderate-to-heavy intensity (M&HI) infections.
An international team of scientists led by those at Ghent University (Merelbeke, Belgium) defined method-specific thresholds and verified whether they increased the correct classification of M&HI infections in a multi-countries study. They evaluated both WHO and method-specific thresholds for classifying the M&HI infections for novel microscopic methods: McMaster egg counting technique, FECPAKG2 (Techion, Aberystwyth, UK), and Mini-FLOTAC (Federico II University of Naples, Naples, Italy) and DNA-based (qPCR) diagnostic methods (Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands). The samples were also analyzed by Kato-Katz method as the reference method.
The team applied the WHO thresholds, the new microscopic methods mainly misclassified M&HI as low intensity, and to a lesser extent low intensity infection as M&HI. For FECPAKG2, applying the method-specific thresholds significantly improved the agreement for Ascaris (moderate → substantial), Trichuris and hookworms (fair → moderate). For Mini-FLOTAC, a significantly improved agreement was observed for hookworms only (fair → moderate). For the other STHs, the agreement was almost perfect and remained unchanged. For McMaster, the method-specific thresholds revealed a fair to a substantial agreement, but did not significantly improve the agreement. For qPCR, the method-specific thresholds based on genome equivalents per mL of DNA moderately agreed with the reference method for hookworms and Trichuris infections. For Ascaris, there was a substantial agreement.
The authors concluded that their results indicated that method-specific thresholds improved the classification of M&HI infections, but they stressed that validation studies are required before they can be recommended for general use in assessing M&HI infections in programmatic settings. The study also highlights the need (i) to agree on an absolute universal unit for qPCR, (ii) to align the evaluation of diagnostic methods with current STH program goals, and (iii) to define minimal and ideal (optimistic) criteria that diagnostic methods should meet in order to assess M&HI infections reliably. The study was published on July 2, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Ghent University
Techion
Federico II University of Naples
Elisabeth-Tweesteden Hospital
Latest Technology News
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read morePathology
view channel
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








